Non-metastatic breast cancer specific-survival of patients after treatment with adjuvant chemotherapy;Sobrevida específica de pacientes com câncer de mama não-metastático submetidas à quimioterapia adjuvante

Revista da Associacao Medica Brasileira

Volumn 54, Issue 4, 2008, Pages 339-346

  Cintra, Jane Rocha Duarte ^a,b   Guerra, Maximiliano Ribeiro ^a   Bustamante Teixeira, Maria Teresa ^a  

^a FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

^b Hospital 9 de Julho   (Brazil)

Author keywords

Breast cancer; Chemotherapy; Prognosis; Survival analysis

Indexed keywords

ADJUVANT CHEMOTHERAPY; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BRAZIL; BREAST TUMOR; COHORT ANALYSIS; FEMALE; HUMAN; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; SURVIVAL;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BRAZIL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 50249151956     PISSN: 01044230     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0104-42302008000400020     Document Type: Article

References (44)

1. Bray F, McCarron P, Parkin DM. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res. 2004;6(6):229-39.
2. McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cancer: epidemiology, risk factors and genetics. BMJ. 2000;321(7261):624-8.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.
4. Guerra MR, Gallo CVM, Mendonça GAS. Risco de câncer no Brasil: tendências e estudos epidemiológicos mais recentes. Rev Bras Cancerol. 2005;51(3):227-34.
5. Osborne CK, Clark GM, Ravdin PM. Adjuvant systemic therapy of primary breast cancer. In: Harris JR, Morrow M, Lippman ME, Hellman S. Diseases of the breast. 2nd ed. New York: Lippincott-Raven Publishers; 1996. p.548-78.
6. Parkin DM, Whelan SL, Ferlay J, et al., editors. Cancer incidence in five continents. Lyon: International Agency for Research on Cancer; 2002. (v.8, IARC Scientific Publications N.155)
7. International Agency for Research on Cancer. Globocan 2002. [cited 2008 jan 9]. Available from: http://www-dep.iarc.fr/.
8. Ministério da Saúde. Instituto Nacional do Câncer (INCA). Estimativa 2006: incidência de câncer no Brasil [citado 20 jun 2007]. Disponível em: http://www.inca.gov.br/estimativa/2006/.
9. Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, Howe HL, et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin. 2006;56(3):168-83.
10. National Cancer Institute. 2004. [citado 2007 dez 06]. Available from: http://www.cancer.gov/cancerinfo/pdq/treatment/breast/ HealthProfessional#Section27.
11. Ministério da Saúde. Instituto Nacional do Câncer (INCA). Registros Hospitalares de Câncer (RHC) - 1998. Instituto Nacional do Câncer. [citado 2006 dez 14]. Disponível em: http://www.inca.gov.br.
12. Guerra MR. Sobrevida e fatores prognósticos para o câncer de mama em Juiz de Fora, Minas Gerais, na coorte diagnosticada entre 1998 e 2000 [tese]. Rio de Janeiro: Instituto de Medicina Social, Universidade do Estado do Rio de Janeiro; 2007.
13. a ed. Rio de Janeiro: INCA; 2004.
14. Anderson WF, Jatoi I, Devesa SS. Distinct breast cancer incidence and prognostic patterns in the NCI's SEER program: suggesting a possible link between etiology and outcome. Breast Cancer Res Treat. 2005;90(2):127-37.
15. Armitage P, Berry G. Survival analysis. In: Armitage P, Berry G. Statistical methods in medical research. 2nd ed. Oxford: Oxford Scientific Publications; 1987.
16. Matti SA. Adjuvant therapy of primary breast cancer: a review of key findings from the 7th International Conference, St. Gallen, February 2001. Oncologist. 2001;6(4):376-85.
17. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. Ca Cancer J Clin. 2005;55(1):74-108.
18. Urbain JL. Breast cancer screening, diagnostic accuracy and health care polities. J Ass Med Canad. 2005;172(2):210-1.
19. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;5(1):43-66.
20. Sant M, Allemani C, Berrino F, Coleman MP, Aareleid T, Chaplain, G, et al. Breast carcinoma survival in Europe and the United States. Cancer. 2004;100(4):715-22.
21. Mendonça GAS, Silva AM, Caula WM. Características tumorais e sobrevida de cinco anos em pacientes com câncer de mama admitidas no Instituto Nacional de Câncer, Rio de Janeiro, Brasil. Cad Saúde Pública. 2004;20(5):1232-9.
22. Eisenberg ALA. Sobrevida de cinco anos para pacientes com carcinoma ductal infiltrante de mama sem comprometimento de linfonodos axilares. Coorte hospitalar, 1992-1996, Rio de Janeiro, Brasil [tese]. Rio de Janeiro: Escola Nacional de Saúde Pública, Fundação Oswaldo Cruz; 2004.
23. De Moraes ED, Alban LBV, Costa R, et al. Epidemiologia, características tumorais e sobrevida global de 1565 pacientes com câncer de mama em acompanhamento no Núcleo de Oncologia da Bahia, Brasil. Rev Soc Bras Cancerol. 2005; 29(1):4-12.
24. De Abreu E. Câncer de mama feminina em Goiânia: análise da sobrevida em 10 anos na coorte diagnosticada entre 1988-90 [tese]. Rio de Janeiro: Escola Nacional de Saúde Pública, Fundação Oswaldo Cruz; 2002.
25. Pereira WMM. Mortalidade e sobrevida por câncer de mama, no estado do Pará. [dissertação]. Rio de Janeiro: Escola Nacional de Saúde Pública, Fundação Oswaldo Cruz; 2001.
26. De Moraes AB, Zanini RR, Turchiello MS. Estudo da sobrevida de pacientes com câncer de mama atendidas no hospital da Universidade Federal de Santa Maria, Rio Grande do Sul, Brasil. Cad Saúde Pública. 2006;22(10): 2219-28.
27. Field TS, Buist DSM, Doubeni C, Enger S, Fouaysi H, Hart G, et al. Disparities and survival among breast cancer patients. J Natl Cancer Inst Monogr. 2005;35(1):88-95.
28. Hsu JL, Glaser SL, West DW. Racial/ethnic differences in breast cancer survival among San Francisco Bay area women. J Natl Cancet Inst. 1997;89(17):1311-2.
29. Micheli A, Gatta G, Verdecchia A. Studying survival of cancer patients in different in different populations: its potential and role. Tumori. 1997;83(1):3-8.
30. Ruger JPM. Measuring disparities in health care. BMJ. 2006;333(7562):274.
31. De Abreu E. Câncer de mama feminina em Goiânia: análise da sobrevida em 10 anos na coorte diagnosticada entre 1988-90 [tese]. Rio de Janeiro: Escola Nacional de Saúde Pública, Fundação Oswaldo Cruz; 2002.
32. Simon MS, Banerjee M, Crossley-May H, Vigneau FD, Noone AM, Schwartz Z, et al. Racial differences in breast cancer survival in Detroit metropolitan area. Breast Cancer Res Treat. 2006;97(2):149-55.
33. American Cancer Society. Cancer: facts & figures [cited 2007 jun 10]. Available from: http://www.cancer.org/docroot/PRO/content/ PRO_1_1_Cancer_Statistics_2006_presentation.asp.
34. Pereira WMM. Mortalidade e sobrevida por câncer de mama, no estado do Pará. [dissertação]. Rio de Janeiro: Escola Nacional de Saúde Pública, Fundação Oswaldo Cruz; 2001.
35. Brito C, Portela MC, De Vasconcelos MTL. Assistência oncológica pelo SUS a mulheres com câncer de mama no Estado do Rio de Janeiro. Rev Saúde Pública. 2005;39(6):874-81.
36. De Moraes AB, Zanini RR, Turchiello MS. Estudo da sobrevida de pacientes com câncer de mama atendidas no hospital da Universidade Federal de Santa Maria, Rio Grande do Sul, Brasil. Cad Saúde Pública. 2006;22(10):2219-28.
37. Lin Y-C, Chen S-C, Chang H-K. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy. Jpn J Clin Oncol. 2005;35(9):514-9.
38. Repetto BL, Fratino L, Audisio RA, Venturino A, Gianni V, Vercelli M, et al. Comprehensive Geriatric Assessment Adds Information to Eastern Cooperative Oncology Group Performance Status in Elderly Cancer Patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol. 2002;20(2):494-502.
39. Schrag D, Kuntz KM, Garber JE, Weeks JC, Redmond CK, Kavanah M, Cronin WM, et al. Effects of prophylactic mastectomy and oophorectomy on life expectancy women with BRCA1 or BRCA2 mutations. N Engl J Med. 1997;336(20):1465-71.
40. Fisher B, Constantino JP, Wickerham DL. Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371-88.
41. Offit K, Kauff N, Satagopan J, et al. Risk-reducing salpingo-oophorectomy in women with BRCA1 and BRCA2 mutations. In: American Society of Clinical Oncology. Thirty-Eighth Annual Meeting 2002, Orlando. Proc Am Soc Clin Oncol. 2002;21 (abstr 3).
42. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al. The Atac Trialists'group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359(9324):2131-9.
43. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, et al. The Atac Trialists'group. Anastrozole alone or in combination with tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Result of the ATAC (Arimidex®, tamoxifen, alone or in combination) trial efficacy and safety update analysis. Cancer. 2003;98(9):1802-10.
44. Howell A, Cuzick J, Baum M, Buzdar AU, Dowsett M, Forbes JF, et al. The Atac Trialists' GrouP. Results of the ATAC (Arimidex®, Tamoxifen alone or in combination) trial after completion of 5 years adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60-2.